Comparison of three different COVID-19 vaccine platforms (CoronaVac, BTN162b2, and Ad5-nCoV) in individuals with and without prior COVID-19: Reactogenicity and neutralizing antibodies.

Autor: Morales-Núñez JJ; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Muñoz-Valle JF; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Machado-Sulbarán AC; Institute for Research on Cancer in Childhood and Adolescence, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Díaz-Pérez SA; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Torres-Hernández PC; Immunology Laboratory, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Panduro-Espinoza BV; Servicio de Pediatría, Hospital Civil de Guadalajara 'Dr. Juan I. Menchaca' y Departamento de Clínicas de la Reproducción Humana, Crecimiento y Desarrollo Infantil, CUCS, UdeG, Mexico., Gallegos-Díaz de Leon JA; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Munguía-Ramirez CD; Institute for Research on Cancer in Childhood and Adolescence, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico., Hernández-Bello J; Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico. Electronic address: jorge.hernandezbello@cucs.udg.mx.

Publikováno v: Immunology letters [Immunol Lett] 2022 Dec; Vol. 251-252, pp. 20-28. Date of Electronic Publication: 2022 Oct 21.